Continued pain after back surgery does not automatically mean you need another operation. It also does not automatically mean that a regenerative injection is the answer.

We hear from people who have undergone a discectomy, laminectomy, fusion, or several spinal procedures and still struggle with back pain, buttock pain, leg symptoms, or muscle spasms. Their question is understandable: “Can stem cells help me now?”

My first question is what is producing the pain today. A technically successful operation may address one problem while another remains. Pain may also recur because of a new problem. The usefulness of any treatment depends on making that distinction.

What does “failed back surgery syndrome” mean?

The term failed back surgery syndrome is increasingly replaced by persistent spinal pain syndrome type 2, or PSPS-T2. It describes persistent or recurrent spinal pain after surgery without assuming that the surgeon, the patient, or one particular structure is responsible. A 2024 evidence-based review describes causes ranging from recurrent disease and surgical complications to altered spinal mechanics. (1)

Recommendations published in the January 2026 issue of Pain Practice emphasize identifying the pain mechanism, anatomical source, and degree of diagnostic certainty. For a patient, the practical distinction is between pain arising mainly from irritated tissues, injured nerves, altered pain processing, or a combination. The history of surgery alone cannot tell us which treatment will help. (2)

Why can pain continue after a discectomy, laminectomy, or fusion?

Several possibilities deserve consideration:

  • Persistent or recurrent nerve compression, disc herniation, or spinal stenosis.
  • A fusion that has not united, hardware problems, infection, or another surgical complication.
  • Changed loading of nearby joints and tissues, including adjacent spinal levels and the sacroiliac joint.
  • Muscle dysfunction, painful soft tissues, or another pain source outside the operated area.
  • Persistent nerve pain or altered pain processing even after the original structural problem has been addressed.

These possibilities explain why a careful reassessment is more useful than assuming that all postoperative pain has the same cause. They also explain why an injection into one structure cannot be expected to treat every postoperative pain problem. (1) (2)

What about spinal ligaments, muscle attachments, and spasms?

One clinical point I emphasize is that the evaluation should extend beyond the disc. Ligaments, joint capsules, muscles, and tendon attachments help support the spine. Painful or overloaded tissues around the low back and pelvis may deserve attention, particularly when symptoms are reproduced by movement or examination.

After a fusion, the fused segment no longer moves in its usual way. After a laminectomy, the remaining structures and the extent of the operation matter. Neither history, by itself, proves that a ligament injury is causing the pain.

Muscle spasms are another clue to investigate, rather than a diagnosis. Tenderness or temporary relief after an injection does not prove that a ligament has been structurally repaired. My clinical interest in these tissues should be distinguished from evidence establishing a particular biologic treatment.

For the overlapping symptoms of disc and pelvic pain, see Is your low back pain coming from a disc or the sacroiliac joint?

What should the evaluation include?

I want to know whether the current symptoms are the same symptoms that led to surgery. Did the operation provide a period of relief? Is the pain mainly in the back, or does it travel into the leg? Are there changes in strength, sensation, walking tolerance, or bladder function?

The examination and review of the surgical history help determine which investigations are useful. The 2026 mechanism-based recommendations support describing both the suspected source and how certain that diagnosis is, rather than choosing treatment from an MRI label alone. (2)

Imaging remains important after surgery when symptoms are new or progressing. The American College of Radiology’s low-back-pain criteria address this postoperative situation separately from uncomplicated back pain. Depending on the question, radiographs, MRI without contrast, or MRI before and after contrast may be appropriate; CT can help answer selected questions about bone or hardware. (3)

The MRI is part of the evaluation. The finding must fit the symptoms and examination before it becomes a convincing treatment target. Conversely, progressive neurological symptoms should not be dismissed because some imaging abnormalities are incidental.

For leg-pain evaluation, see sciatica and non-surgical treatment considerations. For symptoms associated with spinal narrowing, see lumbar spinal stenosis treatment options.

Urgent assessment is needed for new bladder or bowel dysfunction, numbness around the groin or saddle area, rapidly worsening weakness, or severe postoperative pain accompanied by fever or wound concerns. These symptoms take priority over elective injection treatment. (3)

Does another back surgery usually help?

Repeat surgery can help when there is a clear, treatable problem. The important question is what the proposed operation would correct and whether that problem explains the symptoms.

A registry study of 4,940 patients found that more previous lumbar operations were associated with worse patient-rated outcomes 12 months after another operation. This supports realistic counseling, but it does not prove that each operation caused the poorer result or that revision surgery is inappropriate for every patient. People needing repeated surgery may have more complex disease. (4)

A study of 422 patients followed patients for two years after lumbar surgery. Eleven percent reported no pain improvement, 28% reported a little to moderate improvement, 44% reported a lot of improvement, and 17% reported complete improvement. These are findings from one study population, not a prediction for an individual patient. They demonstrate that improvement and complete pain relief are different outcomes. (5)

A 2018 observational study explored patient-reported profiles to help guide referral for surgery or multidisciplinary pain management. It should not be turned into a rule that people over 50, people with depression, or people with previous operations should never see a spine surgeon. Decisions require an individual clinical assessment. (6)

What do established treatment approaches emphasize?

The 2026 recommendations favor matching treatment to the mechanism of pain. That may require addressing a structural problem, nerve-related symptoms, physical function, and the effects of persistent pain on daily life. This framework is expert guidance for better treatment selection, rather than proof that one intervention will work for everyone. (2)

A practical plan may include appropriately paced exercise and rehabilitation, medication review, and support for sleep, coping, and return to activity. The 2025 ASIPP regenerative-medicine guidelines describe biologic treatments as possible components of broader care that can include exercise, physical therapy, behavioral approaches, and conventional medical management. (7)

Selected diagnostic or therapeutic procedures may be considered for a suspected source of pain. Spinal cord stimulation is also considered for some people with persistent neuropathic pain, but benefits vary. A randomized trial in patients with chronic radicular pain after lumbar surgery found no significant disability advantage from burst stimulation over placebo stimulation. That result applies to the approach studied and should be part of a balanced discussion of neuromodulation. (8)

What does current research say about PRP and bone marrow concentrate?

“Stem cell treatment” is often used too broadly. Platelet-rich plasma (PRP) is a platelet preparation from the patient’s blood. Bone marrow aspirate concentrate (BMAC, also called BMC) is a mixture of cells and signaling components obtained from bone marrow; it is not a purified or culture-expanded stem-cell product.

The injection target matters as much as the preparation. Research on an injection into a disc does not establish the effectiveness of injections around ligaments or into a joint. A discogenic-pain trial also does not automatically answer the question of pain after fusion or nerve injury.

2025 ASIPP guidelines: limited evidence, with recommendations for selected uses

The ASIPP update rated intradiscal PRP and BMAC, and epidural PRP, as Level III or “fair” evidence, with moderate consensus-based recommendations. Facet-joint PRP/MSC injections and SI-joint PRP had Level IV or limited evidence. Evidence for injections across the functional spinal unit was very low. These are one professional society’s assessments of chronic low back pain; they do not establish that biologics reverse postoperative damage or reliably treat PSPS-T2. (7)

A positive PRP trial needs to be interpreted in context

A 2025 randomized trial enrolled 40 patients with discogenic low back pain and compared intradiscal PRP with methylene blue. At six months, the PRP group had better pain and functional outcomes. However, the trial was small, used an active comparator rather than a sham procedure, and was not a trial of persistent pain after back surgery. MRI measures also did not establish restoration of a normal disc. (9)

A sham-controlled bone marrow trial found no significant advantage

A 2025 double-blind randomized trial included 63 patients with presumed discogenic low back pain: 45 received intradiscal BMC and 18 underwent a sham procedure. There were no significant between-group differences in the primary pain-response outcome or the proportion achieving the specified functional improvement through 12 months. (10)

This is an important counterweight to uncontrolled reports of improvement. It does not settle every question about BMAC, but it means that benefit should not be assumed. It also cannot be used to claim that injections into postoperative ligaments are effective; those are different targets and clinical questions.

What can these injections realistically be expected to do after surgery?

In my clinical reasoning, a localized musculoskeletal pain source deserves different consideration from a loose implant or progressive nerve compression. However, identifying a plausible target does not establish that PRP or BMAC will help it.

The available evidence does not justify promising that these injections will rebuild a postoperative disc, dissolve epidural scar tissue, repair a damaged nerve, strengthen spinal ligaments, or correct a failed fusion. Questions about possible symptom improvement must be discussed separately from claims of structural repair. The evidence varies substantially by target and preparation. (10)

Potential risks include infection, bleeding, pain flares, and injury to nearby structures; spinal procedures require particular attention to technique and patient selection. A treatment described as biologic is still a medical intervention.

Wharton’s jelly: promising laboratory research, with an important evidence gap

Wharton’s jelly is connective tissue within the umbilical cord. Tissue matrix preparations, isolated cells, culture-expanded cells, and extracellular vesicles are different materials. Findings from one should not be presented as proof for another.

A 2025 laboratory study examined matrix-bound nanovesicles isolated from decellularized Wharton’s jelly. Researchers observed effects on inflammatory macrophage behavior and on human disc-cell migration and molecular markers associated with a cartilage-like cell phenotype. This provides a biological reason for further investigation of the material in disc research. (11)

It was not a clinical trial in people with postoperative back pain. It does not establish a dose, injection approach, lasting pain benefit, or safety for this condition. Matrix-bound nanovesicles also should not be assumed to be interchangeable with commercial products labeled “exosomes.”

Exosomes: why orthopedic researchers are interested

Exosomes are small extracellular vesicles involved in communication between cells. Their contents and effects depend on the cells that produced them and how they are prepared.

In a 2025 preclinical study, researchers investigated an injectable hydrogel carrying exosomes derived from umbilical-cord mesenchymal stromal cells grown under low-oxygen conditions. Laboratory and rat-model findings suggested effects on disc-cell senescence and disc degeneration. The work concerns an engineered experimental delivery system, rather than an established injection for patients after back surgery. (12)

These findings are promising as research into cell signaling and tissue biology. They do not demonstrate that exosomes relieve postoperative back pain, reverse stenosis, or repair surgical nerve damage. A result in a rat disc cannot establish a clinical benefit in a person with a fusion, hardware, or several competing pain sources.

The FDA states that there are no FDA-approved exosome products and that the regenerative products addressed in its consumer alert, including Wharton’s jelly-derived products, have not been approved for orthopedic conditions. Research interest and regulatory approval are separate questions. (13)

Persistent pain affects more than the spine

Emotional factors and treatment expectations deserve attention alongside physical findings. Depression, fear of movement, and sleep difficulty should never be used to suggest that someone’s pain is imaginary.

A 2026 Korean database study of 603,272 people after lumbar surgery associated postoperative chronic back pain syndrome with higher rates of psychiatric disorders, several neurological conditions, and mortality. The study used administrative definitions, including diagnostic codes, prolonged gabapentinoid prescriptions, and reoperation. These associations do not prove that back pain caused the other conditions, nor that an injection would prevent them. They support taking the broader burden of persistent pain seriously. (14)

Can stem cells help after failed back surgery?

The honest answer is that we cannot decide from the words “failed back surgery” or from an MRI alone. Some people have a problem requiring surgical reassessment. Others have pain better approached through rehabilitation, pain management, or evaluation of another musculoskeletal source. Evidence for PRP and BMAC remains dependent on the diagnosis and injection target, with important uncertainties.

I want patients to understand both the possibilities and the limits. Having already undergone surgery does not remove the need for a fresh diagnosis. The next treatment should follow the best-supported explanation for the pain you have now.

Related video

Watch Dr. Darrow’s back-pain treatment video. The video provides additional clinical context; the research discussion above explains the current evidence and its limitations.

References

1 van de Minkelis J, Peene L, Cohen SP, et al. 6. Persistent spinal pain syndrome type 2. Pain Practice. 2024;24(7):919–936. doi:10.1111/papr.13379.

2 Thomson S, Simpson B, Huygen FJ, et al. The Implementation of Persistent Spinal Pain Syndrome (PSPS): Mechanism-Based Recommendations. Pain Practice. 2026;26(1):e70104. doi:10.1111/papr.70104.

3 Expert Panel on Neurological Imaging; Hutchins TA, Peckham M, Shah LM, et al. ACR Appropriateness Criteria® Low Back Pain: 2021 Update. Journal of the American College of Radiology. 2021;18(11S):S361–S379. doi:10.1016/j.jacr.2021.08.002.

4 Zehnder P, Aghayev E, Fekete TF, Haschtmann D, Pigott T, Mannion AF. Influence of previous surgery on patient-rated outcome after surgery for degenerative disorders of the lumbar spine. European Spine Journal. 2016;25(8):2553–2562. doi:10.1007/s00586-016-4383-x.

5 Mancuso CA, Reid MC, Duculan R, Girardi FP. Improvement in Pain After Lumbar Spine Surgery: The Role of Preoperative Expectations of Pain Relief. Clinical Journal of Pain. 2017;33(2):93–98. doi:10.1097/AJP.0000000000000383.

6 van Hooff ML, van Dongen JM, Coupé VMH, Spruit M, Ostelo RWJG, de Kleuver M. Can patient-reported profiles avoid unnecessary referral to a spine surgeon? An observational study to further develop the Nijmegen Decision Tool for Chronic Low Back Pain. PLOS ONE. 2018;13(9):e0203518. doi:10.1371/journal.pone.0203518.

7 Manchikanti L, Navani R, Navani A, et al. Comprehensive Evidence-Based Guidelines for Regenerative Therapies in the Management of Chronic Low Back Pain: 2025 Update from the American Society Of Interventional Pain Physicians (ASIPP). Pain Physician. 2025;28(S7):S1–S119.

8 Hara S, Andresen H, Solheim O, et al. Effect of Spinal Cord Burst Stimulation vs Placebo Stimulation on Disability in Patients With Chronic Radicular Pain After Lumbar Spine Surgery: A Randomized Clinical Trial. JAMA. 2022;328(15):1506–1514. doi:10.1001/jama.2022.18231.

9 Wang X, Wang S, Zhang J, Xie G, Zhang J. Platelet-rich plasma for the treatment of discogenic low back pain: a prospective randomized controlled trial. Frontiers in Pain Research. 2025;6:1648772. doi:10.3389/fpain.2025.1648772.

10 Levi D, Tyszko S, Horn S, Pham N, Levin J. Bone marrow concentrate intradiscal injection for chronic discogenic low back pain: A double-blind randomized sham-controlled trial. Interventional Pain Medicine. 2025;4(3):100611. doi:10.1016/j.inpm.2025.100611.

11 Penolazzi L, Zaramella A, Chierici A, et al. Wharton’s jelly-derived nanovesicles for targeting intervertebral disc degeneration. Experimental and Molecular Pathology. 2025;144:105011. doi:10.1016/j.yexmp.2025.105011. A corrigendum was published in 2026 (PMID: 41698859).

12 Zhao X, Shi Y, Sun Z, et al. Injectable hydrogel loaded with exosomes from hypoxic umbilical cord-derived mesenchymal stem cells alleviates intervertebral disc degeneration by reversing nucleus pulposus cell senescence. Regenerative Biomaterials. 2025;12:rbaf039. doi:10.1093/rb/rbaf039.

13 U.S. Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA. Accessed November 11, 2026.

14 Park D, Lee WR, Bang M, Park SJ, Kim JH, Kim HS. Impact of Postoperative Chronic Back Pain Syndrome on the Incidence of Psychiatric and Brain Disorders, and All-Cause Mortality. Journal of Pain Research. 2026;19:582506. doi:10.2147/JPR.S582506.

The post Stem cell therapy for failed back surgery syndrome | Postoperative chronic back pain syndrome appeared first on Stem Cell Institute.

Read Original